Literature DB >> 33389314

Dermatomyositis: immunological landscape, biomarkers, and potential candidate drugs.

Ruxue Yin1, Gangjian Wang2, Lei Zhang1, Tianfang Li3, Shengyun Liu4.   

Abstract

INTRODUCTION: Dermatomyositis (DM) is a rare inflammatory disease characterized by the invasion of the skin and muscles. Environmental, genetic, and immunological factors contribute to disease pathology. To date, no bioinformatics studies have been conducted on the potential pathogenic genes and immune cell infiltration in DM. Therefore, we aimed to identify differentially expressed genes (DEGs) and immune cells, as well as potential pathogenic genes and immune characteristics, which may be useful for the diagnosis and treatment of DM.
METHOD: GSE1551, GSE5370, GSE39454, and GSE48280 from Gene Expression Omnibus were included in our study. Limma, ClusterProfiler, and Kyoto Encyclopedia of Genes and Genomes were used to identify DEGs, Gene Ontology (GO), and perform pathway analyses, respectively. Cytoscape was used to construct the protein-protein interaction (PPI) network. Small-molecule drugs were identified using a connectivity map (CMap), and the TIMER database was used to identify infiltrating cells.
RESULTS: DEG analysis identified 12 downregulated and 163 upregulated genes. GO analysis showed that DEGs were enriched in immune-related pathways. Ten hub genes were identified from the PPI network. Additionally, CMap analysis showed that caffeic acid, sulfaphenazole, molindone, tiabendazole, and bacitracin were potential small-molecule drugs with therapeutic significance. We identified eight immune cells with differential infiltration in patients with DM and controls. Finally, we constructed a powerful diagnostic model based on memory B cells, M1, and M2 macrophages.
CONCLUSIONS: This study explored the potential molecular mechanism and immunological landscape of DM and may guide future research and treatment of DM. KEY POINTS: • We explored the molecular mechanism and immunological landscape of dermatomyositis. • GO analysis showed that DEGs were enriched in immune-related pathways. • We predicted small-molecular drugs with potential therapeutic significance based on bioanalytical techniques. • We identified six immune cells with differential infiltration in patients with DM and controls.

Entities:  

Keywords:  Autoimmune disease; CMap; Dermatomyositis; Differentially expressed gene; GEO; Immune infiltrating cell

Mesh:

Substances:

Year:  2021        PMID: 33389314     DOI: 10.1007/s10067-020-05568-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  39 in total

Review 1.  Dermatomyositis and drugs.

Authors:  A L Dourmishev; L A Dourmishev
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

Review 2.  Polymyositis and dermatomyositis: novel insights into the pathogenesis and potential therapeutic targets.

Authors:  Arash H Lahouti; Lisa Christopher-Stine
Journal:  Discov Med       Date:  2015-06       Impact factor: 2.970

Review 3.  Triggers of inflammatory myopathy: insights into pathogenesis.

Authors:  Brittany L Adler; Lisa Christopher-Stine
Journal:  Discov Med       Date:  2018-02       Impact factor: 2.970

Review 4.  Dermatomyositis: Clinical features and pathogenesis.

Authors:  Madeline E DeWane; Reid Waldman; Jun Lu
Journal:  J Am Acad Dermatol       Date:  2019-07-04       Impact factor: 11.527

5.  Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians.

Authors:  Terrance P O'Hanlon; Danielle Mercatante Carrick; Frank C Arnett; John D Reveille; Mary Carrington; Xiaojiang Gao; Chester V Oddis; Penelope A Morel; James D Malley; Karen Malley; Jonathan Dreyfuss; Ejaz A Shamim; Lisa G Rider; Stephen J Chanock; Charles B Foster; Thomas Bunch; Paul H Plotz; Lori A Love; Frederick W Miller
Journal:  Medicine (Baltimore)       Date:  2005-11       Impact factor: 1.889

6.  HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies.

Authors:  Terrance P O'Hanlon; Lisa G Rider; Gulnara Mamyrova; Ira N Targoff; Frank C Arnett; John D Reveille; Mary Carrington; Xiaojiang Gao; Chester V Oddis; Penelope A Morel; James D Malley; Karen Malley; Ejaz A Shamim; Stephen J Chanock; Charles B Foster; Thomas Bunch; Ann M Reed; Lori A Love; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2006-11

Review 7.  A critical role for immature muscle precursors in myositis.

Authors:  Anne Tournadre; Pierre Miossec
Journal:  Nat Rev Rheumatol       Date:  2013-03-12       Impact factor: 20.543

Review 8.  A gene expression approach to study perturbed pathways in myositis.

Authors:  Steven A Greenberg
Journal:  Curr Opin Rheumatol       Date:  2007-11       Impact factor: 5.006

9.  HLA class II alleles may influence susceptibility to adult dermatomyositis and polymyositis in a Han Chinese population.

Authors:  Xiang Gao; Lei Han; Lan Yuan; Yongchen Yang; Guimei Gou; Hengjuan Sun; Ling Lu; Liming Bao
Journal:  BMC Dermatol       Date:  2014-06-04

10.  Clinical characteristics and prognostic analysis of Chinese dermatomyositis patients with malignancies.

Authors:  Chi Shao; Shan Li; Yuxin Sun; Ying Zhang; Kai Xu; Xin Zhang; Hui Huang
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

View more
  1 in total

1.  Ten genes are considered as potential biomarkers for the diagnosis of dermatomyositis.

Authors:  Lu Xiao; Wei Xiao; Shudian Lin
Journal:  PLoS One       Date:  2021-11-24       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.